PANGAEA ONCOLOGY

Trading sesion


24/06/2022 Close

1.6000

Last price


36.40 mill. €

Capitalisation

0.00

Dif.(%)


1.91

% Year 2022

Last Trade

Date

24/06/2022

Hour

Close

Last

1.6000

Ref.

1.6000

Dif.(%)

0.00

Volume (Shares)

-

Turnover (€x1000)

-

X
24/06/2022 16:00:23
BidAsk
OrdersVolumePricePriceVolumeOrders
12001.56001.60005,0001

Security

Security name

PANGAEA ONCOLOGY

Ticker

PANG

ISIN

ES0105221008

NIF

A-64353584

Shares Admitted

22.747.835

Nominal

0,02 Euros

Capital Admitted

454.956,70 Euros

Trading

Fixing

Liquidity Provider

GVC GAESCO VALORES, S.V., S.A.

Registered Advisor

DCM ASESORES Dirección y Consultoría de Mercados, S.L.

Auditor

ERNST & YOUNG S.L.

Address

CALLE COSO 42, 50004 ZARAGOZA

Contact

info@panoncology.com

Historical Summary

 20182019202020212022 until 24/06

Capital Admitted (thousands of euros)

262338338451455

Shares (x 1,000)

13,11016,88716,88722,53322,748

Period Close Price (euros)

2.22001.70001.60001.57001.6000

Period Last Price (euros)

2.22001.70001.60001.57001.6000

Period High Price (euros)

2.46002.20001.70002.70001.8100

Period Low Price (euros)

2.02001.70000.97001.40001.3600

Capitalisation (thousands of euros)

29,10528,70727,01835,37736,397

Volume (thousands of shares)

1551,5102,8047,531422

Turnover (thousands of euros)

3552,2273,82211,106649

Company Profile

Founded in Barcelona in 2006, Pangaea Oncology is a medical services company focused on precision oncology, personalized medicine based on genetic analyses to improve survival and quality of life for cancer patients.

The company has two main areas of activity: (i) its clinical care division, the Dr. Rosell Oncology Institute (IOR). Based on the concept of personalized medicine, IOR delivers medical oncology services and related activities at four of the largest hospitals of the Quirónsalud Group in Catalonia; (ii) its Diagnostic and R & D services division, providing diagnostic and in-vitro services to IOR patients and Pangaea's portfolio of pharmaceutical clients, including over 15 multinationals. Pangaea is highly invested in technology, focusing on the development of innovative, proprietary diagnostic techniques (its main commercialized asset is Liquid Biopsy), and development of targeted drugs - to early clinical trial stages - through a strategic agreement with Cancer Research Technology, UK.
 
The synergy between these areas forms the foundation of Pangaea's future growth strategy. 

Other Relevant Information

Notices

Relevant Facts until 10/05/2020

Significant participations

Financial Reports

Photo Gallery

To obtain detailed information or information in other formats, please contact BME Market Data at marketdata@grupobme.es or visit the website www.bmemarketdata.es.

The information provided by the different websites of Grupo BME is for internal use only. For any commercial use and/or other usage that involves the redistribution of the information to third parties for a fee, it is required a prior and express permission from BME Market Data. Please contact us at marketdata@grupobme.es.